These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38745766)

  • 1. Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics.
    Montella A; Cantalupo S; D'Alterio G; Damiano V; Iolascon A; Capasso M
    Explor Target Antitumor Ther; 2024; 5(2):374-383. PubMed ID: 38745766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (
    Soria-Chacartegui P; Villapalos-García G; López-Fernández LA; Navares-Gómez M; Mejía-Abril G; Abad-Santos F; Zubiaur P
    Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients:
    Ragia G; Maslarinou A; Atzemian N; Biziota E; Koukaki T; Ioannou C; Balgkouranidou I; Kolios G; Kakolyris S; Xenidis N; Amarantidis K; Manolopoulos VG
    Front Pharmacol; 2023; 14():1248898. PubMed ID: 37781702
    [No Abstract]   [Full Text] [Related]  

  • 4. The Role of
    Abbasian MH; Ansarinejad N; Abbasi B; Iravani M; Ramim T; Hamedi F; Ardekani AM
    Avicenna J Med Biotechnol; 2020; 12(3):157-164. PubMed ID: 32695278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients.
    Pinheiro M; Peixoto A; Rocha P; Santos C; Escudeiro C; Veiga I; Porto M; Guerra J; Barbosa A; Pinto C; Arinto P; Resende A; Teixeira MR
    Pharmacogenet Genomics; 2023 Oct; 33(8):165-171. PubMed ID: 37611150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
    Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
    Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
    Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
    Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients.
    Riera P; Riba M; Bernal S; Virgili AC; Páez D; Moreno ME
    Farm Hosp; 2021 Dec; 45(7):5-10. PubMed ID: 35379107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of pharmacogenetic testing in oncology:
    Wu A; Anderson H; Hughesman C; Young S; Lohrisch C; Ross CJD; Carleton BC
    Front Pharmacol; 2023; 14():1257745. PubMed ID: 37745065
    [No Abstract]   [Full Text] [Related]  

  • 11. Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.
    Wong BYL; Li Z; Raphael MJ; De Angelis C; Hwang DM; Fu L
    J Appl Lab Med; 2024 Mar; 9(2):295-304. PubMed ID: 38084968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (
    Ambrodji A; Sadlon A; Amstutz U; Hoch D; Berger MD; Bastian S; Offer SM; Largiadèr CR
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062841
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Lešnjaković L; Ganoci L; Bilić I; Šimičević L; Mucalo I; Pleština S; Božina N
    Pharmacogenomics; 2023 Jan; 24(2):93-106. PubMed ID: 36636997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
    Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
    Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of DPYD gene variants and phenotype inference in a Southern Brazilian population.
    Botton MR; Hentschke-Lopes M; Matte U
    Ann Hum Genet; 2022 Mar; 86(2):102-107. PubMed ID: 34897655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
    Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
    Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Variations of the
    Farinango C; Gallardo-Cóndor J; Freire-Paspuel B; Flores-Espinoza R; Jaramillo-Koupermann G; López-Cortés A; Burgos G; Tejera E; Cabrera-Andrade A
    J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
    Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
    BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
    Božina N; Bilić I; Ganoci L; Šimičević L; Pleština S; Lešnjaković L; Trkulja V
    Br J Clin Pharmacol; 2022 May; 88(5):2190-2202. PubMed ID: 34780066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
    Malekkou A; Tomazou M; Mavrikiou G; Dionysiou M; Georgiou T; Papaevripidou I; Alexandrou A; Sismani C; Drousiotou A; Grafakou O; Petrou PP
    BMC Med Genomics; 2024 Mar; 17(1):78. PubMed ID: 38528593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.